What a 'sessile serrated polyp' means on your colonoscopy report

Take the phrase one word at a time. A polyp is any small growth rising from the lining of the colon; it is a shape word, not a diagnosis. 'Sessile' is also a shape word: it means flat and broad-based, sitting on the lining like a low dome rather than hanging from a stalk (the stalked kind is called 'pedunculated'). 'Serrated' is the one that names the actual finding: under the microscope, the tiny glands inside this polyp take on a saw-toothed outline, which files it in the serrated family of polyps.

That matters because 'sessile' shows up alone all the time. A procedure note saying 'the polyp was sessile' has told you how the polyp sat, not what it was; plenty of harmless polyps are sessile. Only the full phrase from the pathologist, 'sessile serrated,' names this diagnosis. Patients mix these up constantly, and the mix-up runs both directions: some scare themselves over a flat shape, others reassure themselves out of a real finding.

One more fact, which the report assumes you already know: polyps found during a colonoscopy are almost always removed during the same exam, with a snare or forceps, usually in under a minute. In the usual case, the pathology report exists because the removal already happened, and what you are reading is the lab's description of something that is no longer in you. The one exception to check for: if the procedure note says 'biopsy only,' or you were referred for a second procedure to take the polyp out, the lesion is still there, and that second appointment is the removal. It is the one appointment in this guide that should not wait.

The American Cancer Society's plain-language version is the right starting point: these polyps 'are not cancer, but they are pre-cancerous (meaning that they can turn into cancer), so they need to be removed completely.' Read that sentence closely and notice what it actually says. The risk lives in the future tense, and the remedy is removal. Yours was removed. 'Precancerous' describes what this type of polyp can do over years if nobody takes it out. It is not a measurement of how far along your polyp was, and it does not mean cancer was close.

Patients fill that silence with arithmetic the evidence does not support. One young woman with a 10-millimeter lesion wrote, as fact, that it 'would have turned in 5 or so years.' Another believed polyps 'start being cancerous' at one centimeter. Neither is what the science says. Ten millimeters is a line in the surveillance table (bigger polyps earn closer follow-up), not a line where cancer begins.

The strongest evidence about pace is hiding in plain sight in the guideline itself: for one or two small sessile serrated polyps, fully removed, the 2020 US guideline is comfortable waiting five to ten years before the next look. A committee of specialists whose entire job is preventing colon cancer does not write a five-to-ten-year interval for a finding that turns malignant in five.

For scale, hold two numbers side by side. The serrated pathway, the biological route this polyp family can take, accounts for roughly 15 to 30 percent of colorectal cancers (British Society of Gastroenterology, 2017), with some expert estimates running up to one third (Rex and colleagues, 2012). That is a statistic about the pathway across the whole population, over decades, mostly in polyps nobody found. The average American's lifetime risk of colorectal cancer is about 3.9 percent, roughly 1 in 25 (SEER, 2021 to 2023 data). Your removed polyp was one member of that first statistic, subtracted from it, which is the entire purpose of the exam you just had.

Colon polyps split into two big branches. The adenoma branch (tubular, tubulovillous, villous) is the classic precancerous kind, the subject of the tubular adenoma guide. The serrated branch, named for the saw-toothed look, splits again into three: the hyperplastic polyp (very common, not precancerous), the sessile serrated lesion (this guide), and the rare traditional serrated adenoma, or TSA. Your polyp sits on the branch that can, slowly and via its own biology, progress toward cancer: a chain that runs through a mutation called BRAF and a kind of chemical silencing of genes called methylation, which is why researchers call it a separate 'pathway.' The names are worth a sentence because your report may drop any of them.

Now the three names, because they confuse nearly everyone. The lesion was first characterized in 1996 by two pathologists, Torlakovic and Snover, studying patients whose many 'hyperplastic' polyps were not behaving harmlessly; their 2003 follow-up showed that everyday polyps filed as hyperplastic could be a different lesion (larger, flatter, right-sided) and drew the line under the microscope that split the category. For years it was called a 'sessile serrated adenoma,' then 'sessile serrated adenoma/polyp,' written SSA/P. In 2019, the World Health Organization settled the matter: the term is now 'sessile serrated lesion,' SSL, and its guidance says plainly that the new name replaces the old ones. The word 'adenoma' was retired for a precise reason: adenomas are defined by dysplasia (abnormal-looking cells), and most sessile serrated lesions do not have any. The old name implied a feature the polyp usually lacks.

This is why your report, your friend's report, and half the internet seem to describe different things. 'Sessile serrated adenoma,' 'sessile serrated polyp,' 'SSA/P,' and 'sessile serrated lesion' are one diagnosis across three eras of naming, and management is the same regardless of which name your lab still uses. It is also why a parent's colonoscopy report from years ago is hard to compare with yours: before the category existed, many of these were simply called hyperplastic, and studies re-reviewing old slides have moved a meaningful share of them into the sessile serrated column. The vocabulary moved under everyone's feet.

A colonoscopy pathology report has a fixed anatomy, covered in full in the pathology report guide: a specimen line, a description, and a diagnosis. Go to the diagnosis line first. For this finding it often looks like a real example from a patient's report: 'SESSILE SERRATED LESION, WITHOUT DYSPLASIA.' Some labs write it longer: 'sessile serrated lesion (adenoma/polyp), no dysplasia seen in the planes of sections,' which is the same verdict with the naming history left in.

'Without dysplasia' is the headline, and it is good news. Dysplasia means cells that look abnormal under the microscope, the actual first step of change. The American Cancer Society's definition is usefully blunt: dysplasia describes 'how much your polyp looks like cancer under a microscope.' 'Without dysplasia' means the pathologist looked for that change and found none. Your polyp was caught at the earliest stage it is possible to catch one: the architecture that could someday cause trouble, with none of the trouble started. Most sessile serrated lesions are found exactly here.

If your report instead says 'with cytologic dysplasia' or 'with dysplasia,' the finding is further along and earns a closer follow-up (three years under the 2020 US guideline, the same interval as an advanced adenoma). Two things stay true: it is still not cancer, and it was still removed. One more decoding note for this line: the World Health Organization specifically recommends against grading SSL dysplasia as 'low-grade' or 'high-grade,' so if your report just says 'with dysplasia' and you have read elsewhere about grades, the missing grade is deliberate, not an omission.

The rest of the report is logistics. 'Fragments' and 'in aggregate' describe tissue arriving at the lab in pieces, which is common and usually meaningless for small polyps. 'Piecemeal' in the procedure note means a larger polyp was deliberately removed in sections, often by a technique called endoscopic mucosal resection (EMR), and it matters only for scheduling (step 7).

The location word matters more here than for most polyps: sessile serrated lesions concentrate on the right side of the colon, so 'cecum' or 'ascending colon' on your report is typical of the species (in one screening study, more than 60 percent were right-sided), not a sign of anything worse. And if the diagnosis hedges ('cannot exclude sessile serrated lesion,' 'hyperplastic polyp versus SSL'), step 5 explains why honest pathologists sometimes write exactly that.

Your next-colonoscopy date comes from a published table: the 2020 recommendations of the US Multi-Society Task Force on Colorectal Cancer (Gupta and colleagues, Gastroenterology, 2020). For sessile serrated polyps the ladder runs: one or two, each under 10 millimeters, five to ten years. Three or four small ones, three to five years. Five to ten of them, or any single one 10 millimeters or larger, or any with dysplasia, or a traditional serrated adenoma: three years. And a polyp of 20 millimeters or more removed piecemeal earns a six-month check of the removal site. Whichever finding on your report is the most advanced sets the date; if an adenoma elsewhere in the colon outranks your SSL, the adenoma's row wins.

Now the part no patient page says out loud: every one of those serrated intervals is graded by the task force itself as a 'weak' recommendation resting on 'very low' quality evidence. That is not a scandal; it is the committee being honest that the serrated science is young. But it explains something families run into constantly: one patient's gastroenterologist wanted a repeat in one year while her primary doctor called that excessive, and both were reading the same finding. When the evidence is graded that soft, reasonable doctors weight size, count, location, prep quality, and your family history differently. The interval is a judgment anchored to a table, not a law.

There is a second honest reason intervals wobble: the diagnosis itself is a judgment call at the microscope. In a 2021 study, eight expert gastrointestinal pathologists reviewing the same 120 slides agreed on 'sessile serrated lesion' only moderately (a kappa statistic of 0.44, where 1.0 is perfect agreement; Vennelaganti and colleagues, Gastroenterology). An earlier study found the same across the serrated family (Farris and colleagues, 2008).

The guideline planned for this too: where a practice doubts the local hyperplastic-versus-SSL distinction, it explicitly allows using the SSL schedule for small right-sided polyps read as hyperplastic, to be safe. So when your date lands on the cautious end, you are usually looking at a doctor pricing in known uncertainty, not overreacting. 'Which finding set my interval?' is a fair, answerable question for the follow-up call, and the questions guide has the longer list.

You will read that sessile serrated lesions are 'often missed,' and there is real data behind the phrase: they are flat, pale, often draped in a mucus cap, and they favor the right side of the colon, where bowel prep is least kind. In a 2011 study across fifteen experienced endoscopists, the share of screening patients in whom a doctor found at least one proximal serrated polyp ranged from 1 percent to 18 percent (Kahi and colleagues). Same patients, same equipment era, an eighteen-fold spread. That number is why the phrase 'often missed' exists, and pretending otherwise would be dishonest.

But sit with what that spread means for you specifically, because it points the reassuring direction. Your exam found a sessile serrated polyp, named it, removed it, and scheduled around it. That places your endoscopist among the doctors who look for exactly this lesion, which is the single most protective thing in this entire subject: a Dutch study of 277,555 colonoscopies found that every percentage-point increase in a doctor's detection rate for proximal serrated polyps came with a 7 percent drop in their patients' risk of a cancer appearing before the next exam, what specialists call an interval cancer (van Toledo and colleagues, Lancet Gastroenterology and Hepatology, 2022). The missed-lesion problem belongs mostly to exams where nothing serrated was ever seen. Yours is the opposite case.

The system is also closing the gap on the doctors who do miss them. In 2024, for the first time, the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy made the sessile serrated lesion detection rate a formal, named quality indicator, with a target of finding them in more than 6 percent of screening exams, alongside a raised adenoma detection rate (ADR) target and a longer minimum withdrawal time (Rex and colleagues, 2024). Colonoscopists are now graded on finding this exact lesion. If your report also graded the prep ('fair,' 'poor'), that is the one caveat worth a question, because a shortened interval after imperfect prep is standard practice, not an alarm.

For this polyp, the phrase 'removed completely' carries real weight, and one careful study explains most of the confusing follow-up letters. In the CARE study, researchers biopsied the removal sites of mid-sized polyps (5 to 20 millimeters) right after polypectomy to see whether anything was left behind. For conventional adenomas, 7.2 percent had residual tissue. For sessile serrated polyps: 31 percent (Pohl and colleagues, Gastroenterology, 2013). The flat, indistinct edges that make this polyp hard to see also make its borders hard to judge during removal.

That number is why the follow-up around larger sessile serrated polyps looks different, and why none of it should read as suspicion of cancer. A big flat lesion may be removed 'piecemeal' (in planned sections), and the guideline then asks for a look at the scar in about six months, purely to confirm the site is clean. One patient's portal letter said his next exam was in six months and offered no reason; the reason is this paragraph. Similarly, a doctor's message saying 'I believe all your polyps were completely removed' is not a hedge to worry over; with this lesion, careful doctors talk in exactly that register, and the site check is how belief gets confirmed.

If your polyp was small and came out in one piece, this step mostly is not about you: the 31 percent figure came from mid-sized and larger flat polyps, and small SSLs removed with modern snare technique do well. The practical takeaways fit in two lines. If your report says piecemeal, the six-month check is protocol; keep the appointment. If you are unsure, the two questions worth asking are 'was it removed completely?' and 'do I need a site check?', which are ordinary questions a GI practice answers every day.

First, the report details that genuinely change the plan, all visible on the page: 'with dysplasia' (three-year interval, step 4), size of 10 millimeters or more (three years), five to ten serrated polyps (three years), and piecemeal removal (six-month site check). Each moves the schedule; none of them turns the finding into cancer.

Second, the many-polyps case, because the internet will surface it. Serrated polyposis syndrome is diagnosed only at real thresholds set by the World Health Organization: at least five serrated polyps beyond the rectum, all 5 millimeters or larger with at least two reaching 10 millimeters, or more than twenty serrated polyps spread through the colon, at least five of them beyond the rectum. The count accumulates across colonoscopies, which is why a person can cross the line at a later exam.

Serrated polyposis syndrome (SPS) is rare, on the order of 1 in 2,000 to 1 in 7,000 screening colonoscopies. It does carry genuinely elevated risk, and the same literature's reassuring half is that under annual surveillance that risk falls to about 2 cancers per 1,000 person-years (IJspeert and colleagues, Gut, 2017). One or two sessile serrated polyps do not put you near this diagnosis.

Third, the question every fit thirty-year-old asks the forum at 2 a.m.: what did I do wrong? Threads about this finding are full of people in their twenties and thirties who exercise, skip processed meat, and have no family history, asking what to change. The honest answer is that nobody can point to a habit that put this particular polyp there, and no diet or supplement is proven to prevent the next one. What is proven is the boring pair: the polyp is gone because you showed up, and the surveillance interval exists so the next one, if there is one, meets the same fate. Those are the two levers, and you are already pulling both.

Last, the family question. Screening guidance for your relatives keys off your worst finding, so the report itself is the asset: 'a polyp' in family lore inflates over time, and whether yours was a small SSL without dysplasia or a centimeter-plus lesion with dysplasia is exactly the detail a sibling's doctor will want. Ask your own gastroenterologist whether your specific result changes anyone's start age, and keep the report findable in one place so the answer stays attached to the facts. For adult children coordinating a parent's care, that one saved PDF is the difference between a precise answer and a guess.